Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: March 6, 2007
Last updated: May 31, 2012
Last verified: February 2011
This is a single centre, randomised, double blind, two-way crossover study, to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dry powder GW685698X (800?g) containing magnesium stearate. Magnesium stearate is an excipient added to improve the physical stability of inhaled dry powder formulations. Male and female patients with mild/moderate asthma will be randomised to determine which order they receive a single inhaled administration of GW685698X (800?g) with and without magnesium stearate. There will be a wash-out period of at least 5 days between doses.

Condition Intervention Phase
Drug: GW685698X
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Two-way Crossover Study, to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Inhaled Administration of GW685698X (800?g) With and Without Magnesium Stearate, in Mild/Moderate Asthmatic Patients.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Safety and tolerability: Vital signs: for 48 hours 12-lead ECG including QT, QTc, PR and QRS intervals for 48 hours PEFR, FEV1 for 48 hours Laboratory safety tests (clinical chemistry, haematology, urinalysis) at predose Adverse events for 46 days [ Time Frame: Vital signs: for 48 hours ]

Secondary Outcome Measures:
  • Plasma GW685698X concentrations and pharmacokinetic parameters (AUC, Cmax, t1/2, tmax) following single inhaled doses in mild/moderate asthmatic patients for 48 hours. Weighted mean serum cortisol (0-24 h) on Day 1. [ Time Frame: following single inhaled doses in mild/moderate asthmatic patients for 48 hours. ]

Enrollment: 20
Study Start Date: February 2007

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Clinically stable persistent mild/moderate asthma within the 4 weeks preceding the screening visit,
  • screening pre-bronchodilator FEV1 >or=60 % predicted,demonstrate the presence of reversible airway disease, defined as an increase in FEV1 of >or= 12.0% over the max of the three screening measures and an absolute change of

    >or= 200 mL within 30 minutes following a single 400 mcg salbutamol dose, male or female (of non child bearing potential or meet the contraception criteria),

  • BMI 19-31 kg/m2,
  • Non-smoker,
  • refrains from use of prohibited medication within the specified timeframes

Exclusion criteria:

  • Pregnant or nursing females
  • History of life threatening asthma
  • Subjects who are unable to stop taking protocol defined prohibited medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00444509

New Zealand
GSK Investigational Site
Wellington, New Zealand, 6035
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00444509     History of Changes
Other Study ID Numbers: HZA108799 
Study First Received: March 6, 2007
Last Updated: May 31, 2012
Health Authority: New Zealand: Health and Disability Ethics Committees

Keywords provided by GlaxoSmithKline:
Asthmatic Patients

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on October 21, 2016